The HIV test is the first of several NGS-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
NEW YORK (GenomeWeb) — Buoyed by positive Phase I data on its microRNA-targeting hepatitis C drug RG-101, Regulus Therapeutics is aiming to begin Phase II testing of the dr
NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a num
NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.
NEW YORK (GenomeWeb) – Benitec Biopharma last week disclosed delays in its efforts to dose patients in a Phase I/IIa trial of its expressed RNAi-based hepatitis C treatment TT-034 and said that it is taking steps to speed subject enrollment.
